Logo image of CMND

CLEARMIND MEDICINE INC (CMND) Stock Fundamental Analysis

NASDAQ:CMND - Nasdaq - CA1850534027 - Common Stock - Currency: USD

1.05  +0.01 (+0.96%)

Premarket: 1.05 0 (0%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CMND. CMND was compared to 198 industry peers in the Pharmaceuticals industry. CMND has a bad profitability rating. Also its financial health evaluation is rather negative. CMND does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CMND has reported negative net income.
CMND had a negative operating cash flow in the past year.
In the past 5 years CMND always reported negative net income.
CMND had a negative operating cash flow in each of the past 5 years.
CMND Yearly Net Income VS EBIT VS OCF VS FCFCMND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

CMND has a Return On Assets of -75.30%. This is in the lower half of the industry: CMND underperforms 70.20% of its industry peers.
CMND has a Return On Equity of -173.75%. This is in the lower half of the industry: CMND underperforms 65.66% of its industry peers.
Industry RankSector Rank
ROA -75.3%
ROE -173.75%
ROIC N/A
ROA(3y)-350.52%
ROA(5y)-233.83%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CMND Yearly ROA, ROE, ROICCMND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CMND so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMND Yearly Profit, Operating, Gross MarginsCMND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

CMND has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CMND has more shares outstanding
CMND has a worse debt/assets ratio than last year.
CMND Yearly Shares OutstandingCMND Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
CMND Yearly Total Debt VS Total AssetsCMND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

Based on the Altman-Z score of -6.23, we must say that CMND is in the distress zone and has some risk of bankruptcy.
CMND's Altman-Z score of -6.23 is on the low side compared to the rest of the industry. CMND is outperformed by 65.15% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that CMND is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.00, CMND is doing good in the industry, outperforming 61.62% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.23
ROIC/WACCN/A
WACCN/A
CMND Yearly LT Debt VS Equity VS FCFCMND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M -6M

2.3 Liquidity

CMND has a Current Ratio of 1.72. This is a normal value and indicates that CMND is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.72, CMND is not doing good in the industry: 63.13% of the companies in the same industry are doing better.
A Quick Ratio of 1.72 indicates that CMND should not have too much problems paying its short term obligations.
CMND has a Quick ratio (1.72) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.72
Quick Ratio 1.72
CMND Yearly Current Assets VS Current LiabilitesCMND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

CMND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 95.72%, which is quite impressive.
EPS 1Y (TTM)95.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CMND. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMND Price Earnings VS Forward Price EarningsCMND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMND Per share dataCMND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CMND!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLEARMIND MEDICINE INC

NASDAQ:CMND (5/20/2025, 8:00:00 PM)

Premarket: 1.05 0 (0%)

1.05

+0.01 (+0.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners13.98%
Inst Owner Change-1.8%
Ins Owners8.07%
Ins Owner Change0%
Market Cap5.39M
AnalystsN/A
Price TargetN/A
Short Float %4.71%
Short Ratio0.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.89
P/tB 1.96
EV/EBITDA N/A
EPS(TTM)-1.32
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.91
FCFYN/A
OCF(TTM)-0.91
OCFYN/A
SpS0
BVpS0.56
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -75.3%
ROE -173.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-350.52%
ROA(5y)-233.83%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.72
Quick Ratio 1.72
Altman-Z -6.23
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.51%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.21%
OCF growth 3YN/A
OCF growth 5YN/A